Frédéric Baron
YOU?
Author Swipe
View article: Development of a humanized mouse model of graft-versus-host disease to assess human regulatory T cell function
Development of a humanized mouse model of graft-versus-host disease to assess human regulatory T cell function Open
Introduction Regulatory T cells (Treg)-based therapies are increasingly used for treating autoimmune or graft-versus-host (GVHD) disease. Given their low frequency, several approaches aimed at amplifying them or at increasing their immunos…
View article: Comparing a Novel Anti-BCMA NanoCAR with a Conventional ScFv-Based CAR for the Treatment of Multiple Myeloma
Comparing a Novel Anti-BCMA NanoCAR with a Conventional ScFv-Based CAR for the Treatment of Multiple Myeloma Open
Multiple myeloma (MM) is an incurable hematologic malignancy arising from clonal plasma cells, with poor long-term outcomes due to inevitable relapse after conventional therapies. Chimeric antigen receptor (CAR) T-cell immunotherapy target…
View article: Venetoclax in combination with hypomethylating agents shows promising activity in Acute Myeloid Leukemia with late relapse post allogeneic stem cell transplant: From the EBMT acute leukemia working party
Venetoclax in combination with hypomethylating agents shows promising activity in Acute Myeloid Leukemia with late relapse post allogeneic stem cell transplant: From the EBMT acute leukemia working party Open
Introduction Allogeneic hematopoietic stem cell transplantation (HSCT) remains a mainstay in the treatment of acute myeloid leukemia (AML), with post HSCT relapse being a challenge. Hypomethylating agents (HMA) [5-azacitidine (AZA) or deci…
View article: Elevation of fetal hemoglobin is a biomarker for response to decitabine in AML: Results of the AML21 randomized phase III trial of the EORTC leukemia group, gimema and german MDS study group
Elevation of fetal hemoglobin is a biomarker for response to decitabine in AML: Results of the AML21 randomized phase III trial of the EORTC leukemia group, gimema and german MDS study group Open
Introduction DNA-hypomethylating agents (HMA) have become standard treatment for patients (pts) with acute myeloid leukemia (AML) who are unable or unwilling to receive intensive chemotherapy. Lack of response or delayed response to therap…
View article: Design of a novel NanoCAR construct that compares well with a conventional ScFv-based CAR targeting BCMA on multiple myeloma
Design of a novel NanoCAR construct that compares well with a conventional ScFv-based CAR targeting BCMA on multiple myeloma Open
These findings demonstrate Nb17-nanoCAR-T exhibits potent anti-myeloma efficacy comparable to scFv-based CAR-T, supporting its potential as a promising therapeutic alternative. Multiple myeloma (MM) is an incurable hematologic malignancy a…
View article: Frequency and Impact of Somatic Co-occurring Mutations on Post-Transplant Outcomes in Acute Myeloid Leukemia: A Multicenter Registry Analysis on Behalf of the EBMT ALWP
Frequency and Impact of Somatic Co-occurring Mutations on Post-Transplant Outcomes in Acute Myeloid Leukemia: A Multicenter Registry Analysis on Behalf of the EBMT ALWP Open
Acute myeloid leukemia (AML) includes genetically defined subsets. In allogeneic hematopoietic cell transplantation (allo-HCT) setting, the frequency and prognosis of gene-gene interactions may differ from those of patients treated with ch…
View article: From spheroids to organoids: next-generation models for CAR-T cell therapy research in solid tumors
From spheroids to organoids: next-generation models for CAR-T cell therapy research in solid tumors Open
Chimeric Antigen Receptor T-cell (CAR-T) therapy is a revolutionary immunotherapy involving the genetic modification of T cells to express chimeric receptors targeting specific tumor antigens. Over the past decade, CAR-T therapy has signif…
View article: Challenging the Adverse Label: Diverse Outcomes of <scp>ELN</scp> 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Allografted in First Remission: From <scp>EBMT ALWP</scp>
Challenging the Adverse Label: Diverse Outcomes of <span>ELN</span> 2022 Adverse Cytogenetic Subgroups in Acute Myeloid Leukemia Patients Allografted in First Remission: From <span>EBMT ALWP</span> Open
According to the European LeukemiaNet (ELN) 2022 classification, acute myeloid leukemia (AML) patients with intermediate or adverse risk are offered allogeneic hematopoietic stem cell transplantation (allo‐HSCT) in first remission. In this…
View article: EEG characteristics of central nervous system graft-versus-host disease
EEG characteristics of central nervous system graft-versus-host disease Open
This retrospective study is the first to describe EEG features of central nervous system involvement in graft-versus-host disease (CNS-GvHD). It shows that CNS-GvHD consistently associates with EEG abnormalities at peak disease severity. E…
View article: Use of machine learning techniques to predict poor survival after hematopoietic cell transplantation for myelofibrosis
Use of machine learning techniques to predict poor survival after hematopoietic cell transplantation for myelofibrosis Open
With the incorporation of effective therapies for myelofibrosis (MF), accurately predicting outcomes after allogeneic hematopoietic cell transplantation (allo-HCT) is crucial for determining the optimal timing for this procedure. Using dat…
View article: The role of allogeneic stem cell transplantation in acute myeloid leukemia with translocation t(8;16)(p11;p13)
The role of allogeneic stem cell transplantation in acute myeloid leukemia with translocation t(8;16)(p11;p13) Open
Acute myeloid leukemia (AML) with translocation t(8;16)(p11;p13) represents a rare entity that has been categorized as a disease‐defining recurring cytogenetic abnormality with adverse risk in the 2022 European LeukemiaNet classification. …
View article: Prediction of Poor Survival after Hematopoietic Cell Transplantation in Myelofibrosis Using Machine Learning Techniques
Prediction of Poor Survival after Hematopoietic Cell Transplantation in Myelofibrosis Using Machine Learning Techniques Open
Introduction: Allogeneic hematopoietic cell transplantation (allo-HCT) can cure myelofibrosis (MF) but requires careful risk-benefit analysis due to its toxicity. This is crucial as effective agents for treating MF have been incorporated i…
View article: Decreased Chronic GvHD with Post-Transplant Cyclophosphamide (PTCY) Compared to ATG in Patients with Myelofibrosis Allografted with Unrelated Donor: A Study from the Chronic Malignancies Working Party of the EBMT
Decreased Chronic GvHD with Post-Transplant Cyclophosphamide (PTCY) Compared to ATG in Patients with Myelofibrosis Allografted with Unrelated Donor: A Study from the Chronic Malignancies Working Party of the EBMT Open
Background Prospective randomized trials have reported a benefit for anti-thymoglobuline (ATG)-based graft-versus-host disease (GvHD) prophylaxis in the setting of allogeneic hematopoietic stem cell transplantation (alloHSCT) using unrelat…
View article: Separation of Gvl Effects from GvHD with Ptcy-Based Gvhd Prophylaxis in Mmud Transplantation: A Study from the ALWP of the EBMT
Separation of Gvl Effects from GvHD with Ptcy-Based Gvhd Prophylaxis in Mmud Transplantation: A Study from the ALWP of the EBMT Open
Background: The efficacy of allogeneic hematopoietic stem cell transplantation (allo-HCT) in patients with acute myeloid leukemia (AML) depends on immune-mediated graft-versus-leukemia (GvL) effects. GvL effects have been closely linked to…
View article: Abatacept vs PT-Cy for GVHD prophylaxis
Abatacept vs PT-Cy for GVHD prophylaxis Open
peer reviewed
View article: CNS manifestations in acute and chronic graft-versus-host disease
CNS manifestations in acute and chronic graft-versus-host disease Open
Despite the growing evidence supporting the existence of CNS involvement in acute and chronic graft-versus-host disease (CNS-GvHD), the characteristics and course of the disease are still largely unknown. In this multicentre retrospective …
View article: Higher survival following transplantation with a mismatched unrelated donor with posttransplant cyclophosphamide‐based graft‐versus‐host disease prophylaxis than with double unit umbilical cord blood in patients with acute myeloid leukemia in first complete remission: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Higher survival following transplantation with a mismatched unrelated donor with posttransplant cyclophosphamide‐based graft‐versus‐host disease prophylaxis than with double unit umbilical cord blood in patients with acute myeloid leukemia in first complete remission: A study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation Open
The best donor option for acute myeloid leukemia (AML) patients lacking an HLA‐matched donor has remained intensively debated. We herein report the results of a large retrospective registry study comparing hematopoietic cell transplantatio…
View article: Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial
Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial Open
We hypothesized that fit older patients with acute myeloid leukemia (AML) treated with decitabine (DEC) would report better health-related quality of life (HRQoL) outcomes than those receiving intensive chemotherapy (IC). We conducted a ph…
View article: Financial Toxicity and Health-Related Quality of Life Profile of Patients With Hematologic Malignancies Treated in a Universal Health Care System
Financial Toxicity and Health-Related Quality of Life Profile of Patients With Hematologic Malignancies Treated in a Universal Health Care System Open
PURPOSE We investigated the association of financial toxicity (FT) with the health-related quality of life (HRQoL) profile of patients with hematologic malignancies treated in a universal health care system. METHODS We did a secondary anal…
View article: Similar efficacy outcomes with peripheral blood stem cell versus bone marrow for autologous stem cell transplantation in acute myeloid leukemia: Long‐term follow‐up of the <scp>EORTC‐GIMEMA</scp> randomized <scp>AML</scp>‐10 trial
Similar efficacy outcomes with peripheral blood stem cell versus bone marrow for autologous stem cell transplantation in acute myeloid leukemia: Long‐term follow‐up of the <span>EORTC‐GIMEMA</span> randomized <span>AML</span>‐10 trial Open
We report here the long-term follow-up of the only prospective randomized trial of autologous hematopoietic stem cell transplantation (auto-HSCT) with peripheral blood stem cells (APBSCT) versus auto-HSCT with bone marrow (ABMT) in acute m…
View article: Encouraging Outcome of AML with t(8;16) Following Allogeneic Stem Cell Transplantation in First Remission - a Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the EBMT
Encouraging Outcome of AML with t(8;16) Following Allogeneic Stem Cell Transplantation in First Remission - a Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the EBMT Open
In the 2022 European Leukemia Net (ELN) risk classification, acute myeloid leukemia (AML) with translocation t(8;16) was newly classified as AML defined by specific cytogenetic abnormalities, associated with unfavorable prognosis. Transloc…
View article: Pre-Transplant Somatic Co-Occurring Mutations (by next generation sequencing) in Acute Myeloid Leukemia: Frequency and Impact on Clinical Outcomes after Allogeneic Hematopoietic Cell Transplantation - a Large Study on Behalf of the EBMT Acute Leukemia Working Party
Pre-Transplant Somatic Co-Occurring Mutations (by next generation sequencing) in Acute Myeloid Leukemia: Frequency and Impact on Clinical Outcomes after Allogeneic Hematopoietic Cell Transplantation - a Large Study on Behalf of the EBMT Acute Leukemia Working Party Open
Background: Acute myeloid leukemia (AML) is a very heterogeneous hematological malignancy, which includes numerous genetically defined subsets. The genomic classification of AML with the identification of mutations in transcription factors…
View article: Cord blood transplantation for AML: Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT study
Cord blood transplantation for AML: Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT study Open
Summary We investigated whether secondary versus de novo acute myeloid leukaemia (AML) would be associated with poor outcomes in adult acute AML patients in first complete remission (CR1) receiving unrelated cord blood transplantation (CBT…